Compare EVTC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTC | IMCR |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2013 | 2016 |
| Metric | EVTC | IMCR |
|---|---|---|
| Price | $27.82 | $32.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $35.80 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 339.7K | 309.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | 27.17 | ★ 30.39 |
| EPS | ★ 0.47 | 0.23 |
| Revenue | ★ $453,869,000.00 | $249,428,000.00 |
| Revenue This Year | $12.68 | $14.57 |
| Revenue Next Year | $6.86 | $8.21 |
| P/E Ratio | ★ $58.67 | $138.89 |
| Revenue Growth | 11.48 | ★ 43.05 |
| 52 Week Low | $21.81 | $27.56 |
| 52 Week High | $34.77 | $40.71 |
| Indicator | EVTC | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 38.66 | 35.99 |
| Support Level | $27.64 | $31.90 |
| Resistance Level | $30.40 | $33.55 |
| Average True Range (ATR) | 0.92 | 1.16 |
| MACD | -0.21 | -0.48 |
| Stochastic Oscillator | 12.57 | 14.45 |
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions. Latin America Payments and Solutions segment derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.